"paper"

On the occasion of the Brain Awareness Week, the European Brain Council and the European Federation of Pharmaceutical Industries and Associations have launched the RETHINKING Alzheimer’s disease White Paper.

Our paper of the month presents the results of a prospective, double-blind, randomised, sham-controlled trial involving 16 centres and investigating the safety and efficacy of unilateral FUSA of the globus pallidus internus in patients with medication-refractory idiopathic PD.

Our February Paper of the Month is a narrative review focusing on epidemiology, pathophysiology and treatment of secondary headache following SARS-COV-2 infection and vaccination, and on the impact of COVID-19 pandemic on primary headache disorders.

Our paper of the month is a retrospective nationwide cohort study that was carried out to determine the clinical sequelae of long covid for a year after infection in patients with mild disease, and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status.

Our paper of the month reports the results of the ENCHANTED 2/MT trial, performed in 44 Chinese hospitals to compare more intensive with less intensive blood pressure management after successful endovascular thrombectomy.

Our authors of the month compared the occurrence of stroke, utilisation of recanalisation procedures, and demographic parameters during the pandemic period with data from the preceding year.

Registration is now open for the launch event of the RETHINKING Alzheimer’s disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00.

Our authors of the month report the results of a multicentre phase-3 clinical trial exploring efficacy and safety of Lecanemab in patients with early AD over a follow-up period of eighteen months.

Our authors of the month conducted a retrospective study of the potential association between COVID-19 and seizures or epilepsy in the six months after infection, using an electronic health records network of 81 million people.

Our research paper of the month presents the results of the Endovascular Treatment for Acute Basilar-Artery Occlusion (ATTENTION) trial; a multicentre, prospective, randomised and open-label trial, conducted in 36 Chinese centres.

The authors of our Covid paper of the month conducted this cross sectional study in southern Germany involving people aged 18–65, confirming the existence of a considerable burden of self-reported post-acute symptom clusters

This month we have selected the guidelines dedicated to the invasive therapeutic pathways for Parkinson's disease, published jointly by the EAN and the Movement Disorder Society-European Section.

Our paper of the month for October investigates vestibular function in patients with dizziness, vertigo and postural symptoms following COVID-19 vaccination.

This month we have selected two phase-2 trials investigating α-synuclein-binding antibodies as potential disease-modifying treatment of Parkinson’s disease.

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.